Capricor Therapeutics’ (CAPR) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Capricor Therapeutics (NASDAQ:CAPR) in a report released on Thursday morning, Benzinga reports. HC Wainwright currently has a $40.00 price objective on the biotechnology company’s stock.

Other equities research analysts also recently issued research reports about the stock. StockNews.com upgraded shares of Capricor Therapeutics from a sell rating to a hold rating in a research report on Wednesday, January 24th. Cantor Fitzgerald assumed coverage on shares of Capricor Therapeutics in a research report on Friday, January 5th. They issued an overweight rating and a $8.00 target price for the company.

Capricor Therapeutics Trading Up 2.2 %

Capricor Therapeutics stock opened at $5.15 on Thursday. The firm has a 50 day simple moving average of $5.58 and a 200-day simple moving average of $4.34. Capricor Therapeutics has a 12-month low of $2.68 and a 12-month high of $8.22.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings results on Thursday, February 29th. The biotechnology company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.21. Capricor Therapeutics had a negative net margin of 88.52% and a negative return on equity of 299.67%. The business had revenue of $12.09 million during the quarter, compared to the consensus estimate of $5.80 million. As a group, equities analysts predict that Capricor Therapeutics will post -0.83 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Capricor Therapeutics stock. Jump Financial LLC purchased a new position in shares of Capricor Therapeutics Inc (NASDAQ:CAPR) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 52,800 shares of the biotechnology company’s stock, valued at approximately $258,000. Jump Financial LLC owned about 0.17% of Capricor Therapeutics as of its most recent SEC filing. Institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.